Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04698343 · ClinicalTrials.gov registry record · NA

Noninvasive Peripheral Nerve Stimulation for Restless Legs Syndrome During Opioid Medication Reduction

A NA study of Restless Legs Syndrome, sponsored by Noctrix Health.

Completed
Registry status
NA
Development phase
21
Enrollment target
2
Study locations

NCT04698343 is a NA study of Restless Legs Syndrome that has completed, run by Noctrix Health. The registered enrollment target is 21 participants, below the 95-participant average among 14 other Restless Legs Syndrome trials with a reported enrollment target (78% lower). The trial reports 2 study locations across 2 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04698343, a NA study of Restless Legs Syndrome, has completed, sponsored by Noctrix Health.

COMPLETED
Registry status
NA
Development phase
21 participants
Enrollment target
2
Study locations

Study Summary

Prospective open-label single-arm feasibility study assessing the tolerability of opioid medication reduction in conjunction with noninvasive peripheral nerve stimulation (NPNS) for patients taking prescription opioids to treat moderate-severe primary RLS.

Conditions Studied

Interventions

  • DEVICE Noninvasive Peripheral Nerve Stimulation (NPNS)

Study Locations (2)

California

  • Mark J Buchfuhrer private practice - Downey

Ohio

  • Ohio Sleep Medicine Institute - Dublin

Trial Details

FieldValue
Enrollment Target 21 participants
Start Date 2021-04-06
Est. Completion 2023-03-28
Phase NA

Sponsor

Noctrix Health

8 total trials

What the Registry Record Tells You About NCT04698343

The ClinicalTrials.gov registry entry for NCT04698343 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 95-participant average among 14 other Restless Legs Syndrome trials with a reported enrollment target (78% lower). The listed sponsor is Noctrix Health, which has 8 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Restless Legs Syndrome appearing as the primary indexed condition, and to 1 intervention - of which Noninvasive Peripheral Nerve Stimulation (NPNS) is the first listed.

NCT04698343 reports 2 study locations spanning 2 distinct geographic areas - top geographies include California, Ohio.

Frequently Asked Questions

What is clinical trial NCT04698343 about?

NCT04698343 is a clinical study titled "Noninvasive Peripheral Nerve Stimulation for Restless Legs Syndrome During Opioid Medication Reduction". Prospective open-label single-arm feasibility study assessing the tolerability of opioid medication reduction in conjunction with noninvasive peripheral nerve stimulation (NPNS) for patients taking prescription opioids to treat moderate-severe primary RLS.

What is the current status of trial NCT04698343?

This trial is currently completed. It is a NA study. The enrollment target is 21 participants. The study started on 2021-04-06. Estimated completion is 2023-03-28.

What conditions does trial NCT04698343 study?

This clinical trial studies the following conditions: Restless Legs Syndrome.

What interventions are being tested in trial NCT04698343?

The interventions under investigation include: Noninvasive Peripheral Nerve Stimulation (NPNS) (DEVICE).

Who is sponsoring clinical trial NCT04698343?

This trial is sponsored by Noctrix Health, which has 8 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04698343 being conducted?

This trial has 2 study locations across California, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Restless Legs Syndrome

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.